Search PubMed⌕ Search

Biomedical subjects

M Ohyama

Publications and source records attributed to M Ohyama.

At least 163 records · Page 9Linked to original sources
PubMed1985

Treatment of head and neck tumors by contact Nd-YAG laser surgery.

The contact Nd-YAG laser system with ceramic rods which has been developed by us was applied to animal experiments and clinical practice. It was confirmed that: 1) this method can be performed at low power of 6 to 8 W in contact laser incision of soft tissue and at 3 to 4 W in localized laser hyperthermia; 2) it permits accurate and precise incision because mis-shots of laser irradiation can be eliminated in the target tissue; 3) it causes less bleeding with minimal damage to adjacent tissue; and 4) it has remarkably high controllability. The contact Nd-YAG laser systems are very useful as one of the new modalities for surgical procedures as well as localized laser hyperthermia in head and neck tumors.

Animals↗
PubMed1985

Fatty acid compositions of triacylglycerols and phospholipids in hen liver lipid before and after sexual maturity.

Changes in fatty acid composition of triacylglycerols and phospholipids of the hen liver lipid on coming into egg production were described. Of the major fatty acids of triacylglycerols, a high content of oleate and low content of stearate and polyenoic acids were observed in the hen liver at all ages (97 to 167 days of age). In contrast, high stearate and polyenoic acids were present in the liver phospholipids at all ages. The oleate content in triacylglycerols was twice that of phospholipids. Triacylglycerols of the hen liver were more unsaturated than phospholipids throughout the experiment. The triacylglycerols of the control and estrogenized male chicks were also more unsaturated than the phospholipids. The distribution patterns of carbon-18 fatty acids (stearate, oleate, and linoleate) of triacylglycerols and phospholipids in liver lipid were examined. Both females and males showed similar distribution patterns of carbon-18 fatty acids of the triacylglycerols. In the phospholipids, all birds also showed similar distribution patterns, but these patterns were distinctly different from those of the triacylglycerols.

Animals↗
PubMed1985

Purification and characterization of rat urinary renin.

Rat urinary renin was purified by a procedure involving ammonium sulfate fractionation, pepstatin-aminohexyl-Sepharose 4B chromatography, ion exchange chromatography and gel filtration. The resulting preparation was essentially homogeneous, as assessed by polyacrylamide gel electrophoresis. The molecular weight of the preparation was estimated to be 39000 by SDS-gel electrophoresis and 40000 by gel filtration. The optimum pH determined with rat angiotensinogen was 7.0, and the Km was 3.6 microM. These properties agreed well with those of purified rat renal renin. The activity of urinary renin was specifically inhibited by anti-renin antibody. These results suggest that urinary renin may originate in the kidney.

Animals↗
PubMed1985

[Clinical studies of S6472 in otorhinolaryngologic infections].

A multicenter cooperative clinical trial was carried out on S6472 (a long-acting preparation of cefaclor (CCL)) to evaluate its effectiveness and safety in the treatment of infectious diseases in the field of otorhinolaryngology. The results are as follows: The clinical efficacy of the drug could be evaluated in 114 patients. An efficacy rate of 65.8% was obtained. The efficacy rate for each disease was found to be 60.0% for acute suppurative otitis media, 12.5% for chronic suppurative otitis media and 44.4% for acute exacerbation of chronic suppurative otitis media. The overall efficacy rate for all cases of suppurative otitis media was 46.4%. The efficacy rate for acute tonsillitis was found to be 93.1%. In the treatment of acute exacerbation of chronic tonsillitis, the efficacy of the drug was rated as excellent or good in all cases. The overall efficacy rate for all cases of tonsillitis was found to be 93.9%. In the treatment of other infectious diseases, the efficacy was rated as excellent or good in all cases. When the cases by resistant organisms to CCL were excluded from the evaluation, the overall efficacy rate of the drug was found to be 74.2%. The bacteria could be identified in 106 cases. Regarding the bacteriological efficacy of single infections, its bacterial elimination rate was found to be 81.1% for Gram-positive bacteria including S. aureus, S. epidermidis, etc., while it was 42.9% for Gram-negative bacteria. The overall elimination rate of bacteria in single infections was 73.1%. The bacterial elimination rate for mixed infections was found to be 85.7%, whereas it was 76.8% when the single and mixed infections were combined. Regarding side effects, 1 case each of diarrhea, soft stool and rash, or 3 cases in total (2.4%), were recorded in a total of 123 patients. However, the severity of each side effect was mild. Regarding abnormal laboratory findings, there were 1 case each of an increase in S-GPT, leukopenia and complication of eosinophilia and thrombocytopenia, or 3 cases in total (7.0%). Each of these adverse reactions was, however, transient in nature, and no serious cases were observed. On the basis of the above results, it was concluded that S6472 can provide sufficient clinical efficacy when it is administered at daily dosage of 750 mg or 1,500 mg in 2 divided doses after the breakfast and dinner.

Administration, Oral↗
PubMed1983

[Clinical effects of chlormadinone acetate (Prostal) on patients with prostatic hypertrophy--with reference to estimation of size and weight of prostate by means of transrectal ultrasonotomography].

Twenty patients with benign prostatic hypertrophy were treated with an anti-androgenic agent, chlormadinone acetate ( Prostal ), 50 mg daily for 3 months. As a control, 20 patients with prostatic hypertrophy were treated with Eviprostat which was a non-hormonal remedy consisting of plant extracts 6 tablets daily for the same duration. Subjective symptoms of 14 patients (70%) in the Eviprostat group and 18 cases (90%) in the Prostal group were improved significantly. Although there were no significant changes in size or weight of the prostate after 3 months in the patients in the Eviprostat group as measured by transrectal ultrasonotomography, remarkable reduction in size and weight of the prostate was observed after 3 months in 11 patients (55%) in the Prostal group. Four cases complained of impotency during Prostal treatment, but no other side effects to the hepatic and/or renal functions were observed.

Aged↗
PubMed1983

[Experimental and clinical studies of cefotiam for the treatment of otorhinolaryngological infections].

Basic and clinical studies on cefotiam (CTM) for the infectious diseases in otorhinolaryngological field were performed and the following results were obtained. The peak value in the serum level of CTM was 18.05 micrograms/ml by 0.5 g administration and 35.2 micrograms/ml by 1 g at 30 minutes after a single intravenous injection. CTM was rapidly excreted from the blood after injection and was detected a little amount in serum at 6 hours after the administration. Tissue concentrations of the drug into palatine tonsil and the mucous membrane of the nasal cavity or maxillary sinus were seen in relatively rapid and good manner. Chemotherapeutic results excepting Pseudomonas aeruginosa infections (3 cases) were excellent in 2 cases, good in 7 cases and poor in 3 cases of 12 patients with the infectious diseases in otorhinolaryngological field. No adverse effects and abnormal values in the laboratory findings were revealed in every patients.

Adolescent↗
PubMed1983

Immunoglobulin M antibody against hepatitis B core antigen for the diagnosis of fulminant type B hepatitis.

We attempted to diagnose fulminant type B hepatitis by the hepatitis B core antibody of the immunoglobulin M class. Of 27 consecutive cases of fulminant hepatitis not due to drug-related causes or type A hepatitis, 11 cases with and 9 without hepatitis B surface antigen in the serum revealed a high activity of immunoglobulin M hepatitis B core antibody by radioimmunoassay (S/N ratio 36.3 +/- 20.3). The remaining 7 cases with presumed non-A, non-B hepatitis, as well as the other 4 cases with drug-related causes, did not show any detectable activity (0.99 +/- 0.16). Serums from 30 asymptomatic carriers did not reveal a high activity of immunoglobulin M hepatitis B core antibody (2.1 +/- 1.2), although titers of non-class-specific hepatitis B core antibody were invariably high. On the basis of the results obtained, immunoglobulin M hepatitis B core antibody may be applied for the diagnosis of type B etiology in cases of fulminant hepatitis with or without hepatitis B surface antigen in the serum.

Adolescent↗